A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Secondary endpoints: details revised at 2 of 5 entries
MinorStudy sites: 62 to 63v16
MinorStudy sites: 61 to 62v15
MinorStudy sites: 60 to 61v14
MinorStudy sites: 59 to 60v13
MinorTrial sites expanded: 52 → 56 locations
Trial sites expanded: 49 → 52 locations
v12
MinorStudy sites: 56 to 58v11
MinorStudy sites: 52 to 56v10
MinorStudy sites: 49 to 52v9
MinorStudy sites: 48 to 49v8
MinorStudy sites: 46 to 48v7
MinorStudy sites: 45 to 46v6
NotableRecruitment opened
Trial sites expanded: 40 → 43 locations
Trial sites expanded: 0 → 40 locations
v5
MinorStudy sites: 43 to 44v4
MinorStudy sites: 40 to 43v3
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 40
Start date changed from estimate of Apr 14, 2026 to Jul 2, 2026
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin).
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide.
Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC \[topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)\]. The estimated duration of the study is approximately 53 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.